Skip to main content

Table 1 Baseline characteristics, laboratory findings, and P2Y12 reaction units

From: Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial

Variables Group A Control C1 p Value Control C2 p Value p Value
    (A vs C1)   (C1vs C2) (A vs C2)
Demographic characteristics
 Men (%) 17 (56.7%) 25 (83.3%) 0.048 67 (85.9%) 0.973 0.002
 Age (years) 70.0 ± 12.8 64.5 ± 12.0 0.091 62.9 ± 10.1 0.486 0.003
 Body mass index (kg/m2) 25.1 ± 3.0 24.6 ± 2.0 0.474 25.2 ± 3.1 0.852 0.320
 Diabetes 14 (46.7%) 8 (26.7%) 0.180 17 (21.8%) 0.777 0.020
 Hypertension 19 (63.3%) 17 (56.7%) 0.792 35 (44.9%) 0.376 0.132
Medication at ER
 Aspirin loading 27 (90.0%) 22 (73.3%) 0.182 70 (89.7%) 0.064 1.000
 Clopidogrel loading 27 (90.0%) 27 (90.0%) 1.000 76 (97.4%) 0.256 0.256
 Beta blocker 26 (89.7%) 23 (76.7%) 0.326 71 (91.0%) 0.095 1.000
 ACEI/ARB 23 (79.3%) 25 (83.3%) 0.950 63 (80.8%) 0.975 1.000
 CCB 1 (3.4%) 1 (3.3%) 1.000 13 (16.7%) 0.126 0.139
 Statin 28 (96.6%) 30 (100.0%) 0.986 77 (98.7%) 1.000 1.000
Major laboratory findings
 Hematocrit (%) 39.7 ± 5.8 41.3 ± 4.3 0.107 43.5 ± 4.4 0.022 0.000
 Platelet (×103/μl) 213.6 ± 49.0 226.1 ± 63.2 0.396 220.9 ± 47.0 0.639 0.483
 Total cholesterol (mg/dl) 162.9 ± 35.6 176.1 ± 51.1 0.261 189.9 ± 38.5 0.132 0.002
 Triglyceride (mg/dl) 129.6 ± 85.7 133.5 ± 92.6 0.867 133.1 ± 81.1 0.982 0.848
 LDL cholesterol (mg/dl) 98.4 ± 40.3 100.2 ± 36.5 0.861 116.9 ± 33.5 0.029 0.022
 Serum creatinine (mg/dl) 0.9 ± 0.6 0.9 ± 0.2 0.819 0.8 ± 0.2 0.262 0.331
 Ejection fraction (%) 57.1 ± 9.1 59.8 ± 6.2 0.201 59.6 ± 6.5 0.852 0.134
 P2Y12 reaction units 277.2 ± 39.2 281.4 ± 38.4 0.672 171.1 ± 51.6 0.000 0.000
  1. ER emergency room, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin-receptor blocker, CCB calcium channel blocker, LDL low-density lipoprotein